For this, researchers evaluated the health records of 1.6 million people suffering from type-2 diabetes who were either takint insulin or GLP-1RA or metformim from 2005 to 2018. During this period, researchers looked for diagnoses of 13 types of cancers associated with obesity over 15 years.
New Delhi: The so-called weight loss drugs have gained a lot of popularity in the past times and because of their ability to combat obesity and to reduce the risk of chronic health problems like diabetes. But according to a new study, skinny jabs like Wegovy could be key to fighting the risk of 10 types of cancer. Researchers discovered that people who took glucagon-like peptide 1 receptor agonists (GLP-1RA) like Wegovy and Ozempic were less likely to be diagnosed with obesity-triggered cancers like those of the bowel, pancreas and stomach.
For this, researchers evaluated the health records of 1.6 million people suffering from type-2 diabetes who were either takint insulin or GLP-1RA or metformim from 2005 to 2018. During this period, researchers looked for diagnoses of 13 types of cancers associated with obesity over 15 years.
It was found that those who were taking GLP-1RA had a lower risk of being diagnosed with these 10 as compared to patients who took insulin. These include: All these diseases are associated with obesity in some way or the other and the excess fat is linked to an increased and even worse prognosis. Researchers also said that there was no dip in cancer risk linked wit.
